Cargando…

Efficacy and safety of Dexrazoxane (DRZ) in sarcoma patients receiving high cumulative doses of anthracycline therapy – a retrospective study including 32 patients

BACKGROUND: Anthracyclines, as the most effective therapy, are the cornerstone of advanced stage sarcoma treatment. However, anthracyclines can also contribute to myocardial dysfunction and congestive heart failure, ultimately limiting the therapeutic potential of the drug. Coadministration of Dexra...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schuler, Markus K., Gerdes, Sebastian, West, Antje, Richter, Stephan, Busemann, Christoph, Hentschel, Leopold, Lenz, Felicitas, Kopp, Hans-Georg, Ehninger, Gerhard, Reichardt, Peter, Pink, Daniel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4977890/ https://www.ncbi.nlm.nih.gov/pubmed/27507014 http://dx.doi.org/10.1186/s12885-016-2654-x

Ejemplares similares

Anthracycline extravasation injuries: management with dexrazoxane
por: Jordan, Karin, et al.
Publicado: (2009)

Dexrazoxane for Preventing Anthracycline Cardiotoxicity in Children with Solid Tumors
por: Choi, Hyoung Soo, et al.
Publicado: (2010)

Efficacy of Dexrazoxane in Preventing Anthracycline Cardiotoxicity in Breast Cancer
por: Macedo, Ariane V.S., et al.
Publicado: (2019)

Efficacy of Dexrazoxane in Cardiac Protection in Pediatric Patients Treated With Anthracyclines
por: Rahimi, Parya, et al.
Publicado: (2023)

The Lack of Synergy between Carvedilol and the Preventive Effect of Dexrazoxane in the Model of Chronic Anthracycline-Induced Cardiomyopathy
por: Szponar, Jaroslaw, et al.
Publicado: (2023)

A cluster-randomised, controlled proof-of-concept study to explore the feasibility and effect of a patient-directed intervention on quality of life in patients with advanced soft tissue sarcoma
por: Schuler, Markus, et al.
Publicado: (2017)

Upfront dexrazoxane for the reduction of anthracycline-induced cardiotoxicity in adults with preexisting cardiomyopathy and cancer: a consecutive case series
por: Ganatra, Sarju, et al.
Publicado: (2019)

Dexrazoxane-afforded protection against chronic anthracycline cardiotoxicity in vivo: effective rescue of cardiomyocytes from apoptotic cell death
por: Popelová, O, et al.
Publicado: (2009)

Cardiac Protective Effects of Dexrazoxane on Animal Cardiotoxicity Model Induced by Anthracycline Combined With Trastuzumab Is Associated With Upregulation of Calpain-2
por: Zhang, Sheng, et al.
Publicado: (2015)

Evaluation of the cost-effectiveness of dexrazoxane for the prevention of anthracycline-related cardiotoxicity in children with sarcoma and haematologic malignancies: a European perspective
por: Dewilde, Sarah, et al.
Publicado: (2020)

Evaluation of electronic patient–reported outcome assessment in inpatient cancer care: a feasibility study
por: Salm, Hanna, et al.
Publicado: (2023)

Cardioprotective Effect of Dexrazoxane in Patients with HER2-Positive Breast Cancer Who Receive Anthracycline Based Adjuvant Chemotherapy Followed by Trastuzumab
por: Kim, In-Ho, et al.
Publicado: (2017)

Scavenging Effects of Dexrazoxane on Free Radicals
por: Junjing, Zhang, et al.
Publicado: (2010)

Dexrazoxane for the treatment of chemotherapy-related side effects
por: Langer, Seppo W
Publicado: (2014)

Dexrazoxane for cardioprotection in older adults with acute myeloid leukemia
por: Vachhani, Pankit, et al.
Publicado: (2017)

Cisplatin/dexrazoxane/doxorubicin: Neutropenia and thrombocytopenia: case report
Publicado: (2020)

Development and Validation of New RP-HPLC Method for the Determination of Dexrazoxane
por: Basaveswara Rao, M. V., et al.
Publicado: (2012)

Dexrazoxane preferentially mitigates doxorubicin cardiotoxicity in female children with sarcoma
por: Narayan, Hari K, et al.
Publicado: (2019)

Induction of thrombospondin-1 partially mediates the anti-angiogenic activity of dexrazoxane
por: Maloney, S L, et al.
Publicado: (2009)

Dexrazoxane ameliorates radiation-induced heart disease in a rat model
por: Li, Long, et al.
Publicado: (2021)

Dexrazoxane does not mitigate early vascular toxicity induced by doxorubicin in mice
por: Bosman, Matthias, et al.
Publicado: (2023)

Effect of Dexrazoxane and Amifostine on the Vertebral Bone Quality of Doxorubicin Treated Male Rats
por: Mwale, F, et al.
Publicado: (2008)

Protective Effects of Dexrazoxane against Doxorubicin-Induced Cardiotoxicity: A Metabolomic Study
por: QuanJun, Yang, et al.
Publicado: (2017)

Utility of Dexrazoxane for the Attenuation of Epirubicin-Induced Genetic Alterations in Mouse Germ Cells
por: Attia, Sabry M., et al.
Publicado: (2016)

Risk Factor Analysis for Secondary Malignancy in Dexrazoxane-Treated Pediatric Cancer Patients
por: Kim, Hyery, et al.
Publicado: (2019)

High anthracycline cumulative dose without cardiac toxicity: A possible protective role of morphine
por: Canale, Maria Laura, et al.
Publicado: (2018)

Early myocardial oedema can predict subsequent cardiomyopathy in high‐dose anthracycline therapy
por: Muehlberg, Fabian, et al.
Publicado: (2022)

Dexrazoxane significantly impairs the induction of doxorubicin resistance in the human leukaemia line, K562
por: Sargent, J M, et al.
Publicado: (2001)

Correction: Utility of Dexrazoxane for the Attenuation of Epirubicin-Induced Genetic Alterations in Mouse Germ Cells
por: Attia, Sabry M., et al.
Publicado: (2016)

Dexrazoxane Shows No Protective Effect in the Acute Phase of Reperfusion during Myocardial Infarction in Pigs
por: Kamat, Pranitha, et al.
Publicado: (2016)

Novel Polyhedral Silsesquioxanes [POSS(OH)(32)] as Anthracycline Nanocarriers—Potential Anticancer Prodrugs
por: Piorecka, Kinga, et al.
Publicado: (2020)

Dexrazoxane Diminishes Doxorubicin-Induced Acute Ovarian Damage and Preserves Ovarian Function and Fecundity in Mice
por: Kropp, Jenna, et al.
Publicado: (2015)

Effects of dexrazoxane on doxorubicin-related cardiotoxicity and second malignant neoplasms in children with osteosarcoma: a report from the Children’s Oncology Group
por: Kopp, Lisa M., et al.
Publicado: (2019)

Native myocardial T1 time can predict development of subsequent anthracycline‐induced cardiomyopathy
por: Muehlberg, Fabian, et al.
Publicado: (2018)

PET/MRI Imaging in High-Risk Sarcoma: First Findings and Solving Clinical Problems
por: Schuler, Markus K., et al.
Publicado: (2013)

Dexrazoxane may prevent doxorubicin-induced DNA damage via depleting both Topoisomerase II isoforms
por: Deng, Shiwei, et al.
Publicado: (2014)

Dexrazoxane improves cardiac autonomic function in epirubicin-treated breast cancer patients with type 2 diabetes
por: Sun, Fangyi, et al.
Publicado: (2016)

Dexrazoxane Protects Cardiomyocyte from Doxorubicin-Induced Apoptosis by Modulating miR-17-5p
por: Yu, Xiaoxue, et al.
Publicado: (2020)

Diffuse myocardial fibrosis by T(1)-mapping in children with subclinical anthracycline cardiotoxicity: relationship to exercise capacity, cumulative dose and remodeling
por: Tham, Edythe B, et al.
Publicado: (2013)

Early Detection of Anthracycline-Induced Cardiotoxicity in Long-Term Survivors of Acute Lymphoblastic Leukemia Treated with Low Cumulative Dose
por: Salvo, Giovanni Di, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_hdduke71obiutmt7b9r0m04s1a